<DOC>
	<DOC>NCT00577850</DOC>
	<brief_summary>The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.</brief_summary>
	<brief_title>Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>have medical history documentation verifying postmenopausal status of at least 2 years (natural or surgical). If not documented, confirmation will be required using estradiol &lt; 20 pg/mL and follicle stimulating hormone (FSH) &gt; 40 IU/mL; have osteopenia or osteoporosis (&lt; 1.002 g/cm2 Lunar or &lt; 0.882 g/cm2 Hologic) as determined by DXA of the lumbar spine (AP or PA view, L1L4). This corresponds to a Tscore of approximately &lt; 1.5. any clinically significant outofrange laboratory values and vital signs, a clinically significant cardiovascular, hepatic, renal, or parathyroid disease, in the opinion of the Investigator a known hypersensitivity to bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>